Global biotechnology company Alvotech S.A. (NASDAQ:ALVO) announced on Monday the European launch of Gobivaz (golimumab), its biosimilar to Simponi (golimumab), also known as AVT05 (prefilled syringe and autoinjector).

Gobivaz is the first marketed biosimilar to Simponi globally. It is being commercialised exclusively in Europe by Alvotech's partner, Advanz Pharma Holdco Limited.

In the UK, the launch is supported by an NHS England tender award, providing a framework for adoption within NHS services and improving access to biologic treatments for immune-mediated inflammatory diseases. Availability across other EEA markets will follow national pricing and reimbursement processes.

Approval of Gobivaz was based on comprehensive analytical, pre-clinical, and clinical studies demonstrating biosimilarity to the reference product. The medicine is available in the same presentations and dosage forms as Simponi and is manufactured at Alvotech's facility in Iceland.